Want to see TSE:DRUG full AI Analyst Report?
Bright Minds Biosciences (DRUG) Stock Forecast & Price Target
DRUG Analyst Ratings
DRUG Stock 12 Month Forecast
Average Price Target
CAD 230.76▲(199.69% Upside)Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Rudy Li | Wolfe Research | CAD 209.47 | buy | 172.04%Upside | Initiated | 10/15/26 | ||
| Francois Brisebois | LifeSci Capital | CAD 203.88 | buy | 164.78%Upside | Initiated | 10/03/26 | ||
| Yasmeen Rahimi | Piper Sandler | CAD 307.22 | buy | 298.99%Upside | Reiterated | 10/01/26 | ||
| Patrick Trucchio | H.C. Wainwright | CAD 202.49 | buy | 162.97%Upside | Reiterated | 09/21/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Reiterated | 08/16/26 | ||
| Andrew Tsai | Jefferies | CAD 202.49 | buy | 162.97%Upside | Initiated | 04/12/26 | ||
| Thomas Shrader | BTIG | CAD 205.28 | buy | 166.60%Upside | Reiterated | 03/30/26 | ||
| Charles Moore | Robert W. Baird | CAD 198.30→CAD 175.95 | buy | 128.51%Upside | Reiterated | 02/13/26 | ||
 Unknown AnalystNot Ranked | Chardan Capital | CAD 111.72 | buy | 45.09%Upside | Initiated | 12/31/25 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Rudy Li | 10/15/26 | CAD 209.47 | buy | 172.04%Upside | Initiated | Wolfe Research | ||
| Francois Brisebois | 10/03/26 | CAD 203.88 | buy | 164.78%Upside | Initiated | LifeSci Capital | ||
| Yasmeen Rahimi | 10/01/26 | CAD 307.22 | buy | 298.99%Upside | Reiterated | Piper Sandler | ||
| Patrick Trucchio | 09/21/26 | CAD 202.49 | buy | 162.97%Upside | Reiterated | H.C. Wainwright | ||
| Joseph Thome | 08/16/26 | ― | buy | ― | Reiterated | TD Cowen | ||
| Andrew Tsai | 04/12/26 | CAD 202.49 | buy | 162.97%Upside | Initiated | Jefferies | ||
| Thomas Shrader | 03/30/26 | CAD 205.28 | buy | 166.60%Upside | Reiterated | BTIG | ||
| Charles Moore | 02/13/26 | CAD 198.30→CAD 175.95 | buy | 128.51%Upside | Reiterated | Robert W. Baird | ||
| Unknown AnalystNot Ranked | 12/31/25 | CAD 111.72 | buy | 45.09%Upside | Initiated | Chardan Capital |
Best Analysts Covering Bright Minds Biosciences
Copying Thomas Shrader's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +26.44% per trade.
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +65.47% per trade.
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +28.00% per trade.
DRUG Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 6 | 5 | 5 | 5 | 8 |
In the current month, DRUG has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DRUG average Analyst price target in the past 3 months is 230.76.
DRUG Financial Forecast
DRUG Earnings Forecast
Next quarter’s earnings estimate for DRUG is -CAD 1.61 with a range of -CAD 2.49 to -CAD 0.61. The previous quarter’s EPS was -CAD 0.24. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
DRUG Sales Forecast
Next quarter’s sales forecast for DRUG is CAD 0 with a range of CAD 0 to CAD 0. The previous quarter’s sales results were CAD 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.